New hope for bile duct cancer: experimental drug faces final test
NCT ID NCT07582315
First seen Jun 24, 2026 · Last updated Jul 24, 2026 · Updated 4 times
Summary
This Phase 3 trial tests a new drug called BL-B01D1 against standard chemotherapy in 538 people with advanced biliary tract cancer that has worsened after prior treatments. The goal is to see if the new drug helps people live longer. The study is not yet recruiting.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- BL-B01D1 (a drug given by IV infusion every 3 weeks)
- What this could lead to
- If successful, this could provide a new treatment option for people with advanced biliary tract cancer who have run out of standard therapies.
- What could go wrong
- This is an early Phase 3 trial, so results are not guaranteed. The new drug may not improve survival or could have side effects that outweigh benefits.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for BILIARY TRACT CANCER are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Beijing Cancer Hospital
RECRUITINGBeijing, Beijing Municipality, China
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a smart drug home in on Hard-to-Treat cancers?
- Can a new immunotherapy combo shrink Hard-to-Treat tumors?
- Can two targeted drugs boost chemo against a rare Bile-Duct cancer?
- New drug cocktail aims to outperform standard immunotherapy in bile duct cancer
- Liver cancer registry aims to uncover new biomarkers from thousands of patients
- Triple-Drug cocktail targets Hard-to-Treat biliary cancers